The document discusses Electro Cancer Therapy (ECT), a cancer treatment method that uses low voltage direct current to destroy tumor cells. ECT has shown success in treating various cancer types with few side effects compared to conventional treatments. A typical ECT session involves inserting electrodes into the tumor and applying a current for 2-3 hours. This causes necrosis of the tumor through electrolysis and an altered electrolytic environment, while leaving healthy tissue unharmed. Studies at clinics in China found ECT achieved a 72% effective rate for lung cancer patients in the short term and high 1-year survival rates. ECT is a promising treatment that warrants further study.

1. BUDWIG CENTER
ECT - Electro Cancer Therapy
By far, the most exciting development in cancer
treatment is ECT. We continue to see outstanding
results for our patients who have received ECT at
the clinic, and have remained cancer free for
several years after the procedure. ECT is highly
effective for patients with certain cancers, mainly
prostate, cervical, vulva, skin, breast, lung, head
and neck, and ECT is even having success with
some cancers that are usually more difficult to
treat, such as stomach, liver and pancreatic
tumours. It is not unusual for a tumour to be
reduced by fifty percent, after the first ECT
treatment.
Many of our patients choose ECT to avoid the unpleasant effects of conventional
cancer treatments that can impact heavily on their lives.
Usually just one session of two or three hours the ECT causes the necrosis (death to
the cancer tumor) and no more is needed. ECT is some cases would be a natural
option to surgery
It is a highly promising and often successful gentle treatment modality which seems to
be widely applied in China and in some European venues such as Germany, Austria,
Holland, Spain, France and Italy. It involves the targeted application of a few milliamps
biological electrical DC current to cancerous growths which often results in the
complete destruction of malignant tumors. Applied as outpatient treatment, it is
superior to surgical excision both because no residual cancer cells are able to survive
the process and in respect to expenses incurred.
How it works
ECT starts to work through the metabolic system of the tumour cell and has a positive
influence on the immunisation process. After the patient receives a local aesthetic and mild
sedative electrical poles (electrodes) which cause low voltage direct current to flow through
the area are attached in and on the tumorous areas. The electrical resistance of the
tumour cells is reduced so that the low voltage current can only focus to cause damage
to these but not to the healthy tissue. In this manner, growths are caused to gradually
die off in a sterile state (aseptic bionecrosis), often in a single session with a duration
of up to three hours. The cancer tissue is now rejected by the healthy body by degrees
www.BudwigCenter.com 1

2. and/or degraded by the immune system’s scavenger cells (phagocytes). During a
treatment, an electrical field is created and loaded particles (ions) are drawn to the
respective poles (electrolysis), for example Na+ and H+ to the cathode (negative pole)
and Cl- to the anode (positive pole). This results in the creation of an alkaline
environment around the cathode and an acidic environment around the anode. The Ph
values are in both cases far from the physiological area and have a destructive effect
on the tissue
Here are some cases of cancer treated at the clinic by Dr. Lopez
Tumor on Arm BEFORE ECT ECT - Facial Tumor
Arm totally healed in 30 days
ECT - Breast Adenocarcinoma
Necrosis of tumor (death) 1 week later Tumor gone
[Note: All ECT Therapy sessions are performed by Dr Lopez in
a Medical Clinic]
3 hours later necrosis and tumor
falls out for natural healing to
now start
The membrane potentials alter when the electrolytic environment in and around the
cells is changed. The membrane becomes perforated in the accelerated ion flow and
disturbances in the metabolic functions and intercellular structures take place. The cell
becomes vulnerable to immune cells, because these are no longer electrically repelled.
www.BudwigCenter.com 2

3. At the same time, tumour antigens are released and increasingly recognised by the
attracted immune cells. A renewed creation of metastases is effectively counteracted
because the current is already active during the attachment of the electrodes and any
tumour cells which may be released are held in the electrical field. Advantage of the
ECT electro-tumor therapy (also called Galvano-therapy)
Another tremendous advantage that needs to be emphasized is that in the ECT
(electro-tumor therapy) the risk of metastasis formation can be practically excluded,
since such a preventive measure is counteracted. With surgery there is always the rest
that some cancer “seeds” or “threads” remain and the tumor grows back. With ECT
the necrosis (death) effect on the cancer tumor literally causes the entire mass to die
and be expelled naturally by the body
A tumor, like the rest of our body, is composed of individual cells. This complementary
method puts the body in a position to defeat the cancer and improve the wellbeing of
the patient.
The name “Electro-Cancer Therapy” in spirit means that not cause the current in and
for the formation of hydrochloric acid, the cure, but also the self through the body is
initiated when it receives the current signal. Thus, the tumor and the immune system
loses its camouflage starts with the defence against malignant tissue, put it simply
activate the natural healing abilities.
How much is an ECT treatment and how long does it take?
A current treatment takes between two and three hours and is computer controlled,
so that the doctor can precisely control the processes in the body.
The following articles while furnishing scientific details will also give an excellent
general introduction to the subject:
• Types of Tumors Responding to Galvanotherapy
• Electrochemical Tumor Therapy (ECT) for Malignancies
• Bio-Electric Therapy (BET) For the Elimination of Malignant Tumors
• Prof. Dr. Yu-Ling Xin’s Treatment Statistics Concerning ECT (Electro Chemo
Therapy)
• Important Addenda
Particular tumor types respond well to ECT….
• Breast cancers
• Mouth and throat cancers
• Esophageal and stomach cancers
• Lung cancers
• Vaginal cancers
www.BudwigCenter.com 3

4. • Melanomas and basal-cell carcinomas
• Skin metastases
• Lymph node metastases
• Liver metastases
• Mycosis fungoides
• Rectal cancer & anal cancer
The use of ECT for malignant tumor removal has many advantages. Such benefits
consist of the following:
a. The organ involved is preserved with no problematic scarring.
b. The electrical needles are applied under local anesthesia without risks.
c. None of the side effects which may be connected with general anesthesia are
present.
d. No damage occurs to healthy tissue.
e. As a result of lysed tumor components being presented to the immune system for
removal, an additional immune stimulation takes place.
From receiving ECT, certain types of cancer patients benefit greatly. Such malignancy
types include:
those with small primary tumors of less than 5 cm in diameter. At the Budwig
Center we treat every size of tumors even 10 cm, however it would take 4 or 5
sessions in such cases
those with solitary metastases, especially in the skin and lymph nodes;
those with recurrences in the region of an operation such as a mastectomy
scar;
those who have inoperable external tumors.
Clinical Study done in China with ECT
Effectiveness of Electrochemical Therapy in the Treatment of
Lung Cancers of Middle and Late Stage in China Study
Xin Yu-Ling, Xue Fu-Zhou, Ge Bing-Sheng, Zhao Feng-Rui, Shi Bin, and Zhang Wei
(Department of Thoracic Surgery, China-Japan Friendship Hospital,Beijing 100029)
ABSTRACT
Objective To investigate the effect of electrochernical therapy (ECT) in the treatment
of middle and late stage lung cancers.
Materials and Methods 386 cases (287 males and 99 females) with middle and late
stage cancers were treated with ECT. The oldest was 78 years old and the youngest
was 25 with an average age of 51 years. Two hundred and three patients had got
squamous cell carcinoma; 138 Aden carcinoma and 45 undifferentiated cancer.
Diameters of the cancer were listed as follows: 153 cases were 4.0-6.0 cm, 82 cases
www.BudwigCenter.com 4

5. 6.1-8.0 cam, 102 cases 8.1-10.0 cm and 49 cases >10.1 cm. In this group, none was at 1
stage, 103 cases were at II stage, 89 cases lIla, 122 cases HIb and 72 cases IV. Among
386 cases, 152 cases (39.4 %) were with hypertension, heart disease etc. Anode and
cathode platinum electrodes were inserted accurately into the tumour mass. Distance
between two electrodes was 2-2.5 cm. Electrodes were connected to a special ECT
instrument. The current was maintained at 6-8 V and 80-100 mA. 100 coulombs is
applied for treating 1 cm diameter of tumour mass.
Results: Short term effectiveness In 386 cases, 99 cases (25.6 %) were CR, 179 cases
(46.4 %) PR, 59 cases (15.3 %) NC and 49 cases (12.7 %). Effective rate (CR +PR) was 72
% (278 cases). Long term effectiveness One to have year survival rates were 86.3 %‚
76.4 %‚ 58.8 %‚ 39.9 % and 29.5 %‚ respectively.
Conclusion : ECT is used easily, effective, safe, less traumatic and makes patients
recover quickly. This is a new and effective method to treat patients with tumours who
are inoperable and cannot receive chemotherapy or radiotherapy.
Electrochemical therapy - lung cancer
Electrochemical therapy (ECT) is a method to kill tumours by inserting platinum
electrodes into the tumour and connecting electrodes to a direct-current instrument.
Free chiorine, oxygen and hydrogen are produced due to electrolysis in the tumour
tissue. And there is strong alkalinity and acidity appeared at cathode and anode,
respectively. All the effects can destroy tumour cells. As early as 1970‘s, ECT has been
used to treat malignant tumours. In 1983, B. Nordenström (1) published a manuscript
describing systematically the resuits of fundamental experiments and clinical
therapeutic effectiveness of ECT.
Since 1987, based on the experiences of B. Nordenström (2), we have made
experimental study on ECT and applied it to clinical practice (3). By the end of 1994,
more than 6600 cases with various kinds of tumours had been. treated with ECT in
about one thousand hospitals in China. The total effective rate (CR + PR) was 60—80 %
in different hospitals. At the First International Symposium on ECT of Cancers held in
Beijing in 1992, we reported the application of ECT to 2516 cases of various kinds of
tumours. The total effective rate was 78.1 % (4).
In this paper, ECT of 386 cases of middle and late stage lung cancers from October
1987 to February 1989 was reported.
Clinical data
Of the 386 cases, 287 cases were male and 99 female. The oldest was 78 years old and
youngest 25; with an average age of 51 years. The diameters of tumours measured on
X-ray film were 4-6 cm in 82 cases, 6.1- 8.0 cm 153 cases, 8.1-10.0 cm 102 cases and
>10.1 cm 49 cases. There were 151 patients (39.1 %) bearing tumours >8.0 cm.
According to pathological examination, 203 cases belonged to squamous cell
carcinoma, 138 Aden carcinoma; and 45 undifferentiated carcinoma. (Table 1)
www.BudwigCenter.com 5

6. TNM classification of 386 cases included 11103 cases (26.7 %)‚ lIla 89 cases (23.1 %)‚
IlIb 122 cases (31.6%) and IV 72 cases (18.6 %). The number of cases at middle stage (II
+ lIla =192) was about the same as that of late stage cases (Ilib + IV =194). (Table 2)
Metastases were more common in cases with lung adenocarcinoma (50.0 %) than that
in squamous cell carcinoma (37.5 %) or undifferentiated carcinoma (12.5 %). Through
lymphatic system, there were metastases to pleura (21 cases), cervical lymph nodes
(18 cases) and liver (6 cases); and through blond stream to bone (16 cases) and chest
wall (11 cases).
In the 386 cases, 39 cases had thoracotomy, 32 cases received radiotherapy (over 4000
cGy), 66 cases received chemotherapy three times, and 65 cases received traditional
Chinese medicine for 4-6 weeks. All these treatments were of no effect to the patients
before they came to have ECT.
As for complications of the 386 cases, there were 39 cases accompanied with
hypertension and 41 cases with coronary heart disease, 31 with chronic bronchitis and
emphysema (lung vital capacity <40 % of normal value) and 41 with diabetes.
Therapeutic method
Either of the two types of therapeutic instruments was used: (1) Type BK 91A with
adjustable voltage, ampere and electricity quantity buttons and devices for presenting
time and auto-alarm. (2) Type BK 92A with Computer to control the above functions. In
addition there are expert systems with video picture showing the size of tumour,
automatic calculation of the number of electrodes and functions for recording, printing
and storing data. Flexible sort or hard platinum electrodes were used according to the
conditions of tumour location and constitution. Local, subdural or general anaesthesia
was used according to patients‘ conditions.
For those cases without thoracotomy, insertion of electrodes was done under X-ray or
CT monitoring. A stylet with insulating tubing outside was inserted first into the
tumour, then the stylet was withdrawn out. The electrodes then inserted in through
the tubing and passing all through the tumour mass. The insulating tubing was, then,
used to protected normal tissue against damage by electricity. After insertion of all the
electrodes, the patient was asked to lie on bed calmly.
Electrodes were, then, connected to the instrument. Voltage was gradually raised up
to the desired voltage and current was raised up accordingly and maintained at 40-60
or 80-100 niA. The effect of ECT with lower amperage (40-60 mA) and longer duration
(2-2.5 h) is better than that of ECT with higher amperage (100-150 mA) and shorter
duration (1-1.5 h). This is because that electrolysis needs a longer time to destroy
turnour tissue. 4V and 20 mA are the minimal limit for ECT. Experimental results
showed that about 100 coulomb per 1 cm of diameter of tumour tissue is needed for
killing effects. Cicatricial tumours, with less electrolytes in them, need more electricity,
while squamous cell carcinomas, with more electrolytes in them, need a lower
quantity of electricity.
www.BudwigCenter.com 6

7. Our experimental results and clinical experiences showed that the radius of tumour
tissue killed area around each electrode is about 2 cm. The distance between
electrodes, thus, should not exceed 2.5 cm. Based on the size and shape of tumour,
the number of electrodes could be determined. Usually, anodes are placed in the
centre and cathodes near the periphery of tumour, with a distance not more than 2 cm
to the edge of tumour in order to prevent normal tissue from electricity damage.
Complications of ECT The main complication, when happened, was traumatic
pneumothorax occurring usually with the central type of lung cancer or lung cancer
with chronic bronchitis and emphysema. The incidence was 14.8 % (57/3 86). In the 57
cases, 25 had their lungs collapsed by more than 1/3, which were treated immediately
with pleural cavity drainage; 32 had only small area of pneumothorax with no
breathing difficulty, hence, no treatment was given and ECT carried on continuously.
As a preventive measure, oxygen breathing and injection of codeine and diazepam to
keep patients in a calm condition could reduce the incidence of pneumothorax.
Therapeutic effectiveness The therapeutic effectiveness feil into CR, PR, NC and PD
according to the standards by WHO in 1978. Short term effectiveness can be seen in
Table 3. The total effective rate
72.0 %. And effective order of short term effectiveness is squamous cell carcinoma
(83.3 % adenocarcinoma (63.8 %) and undifferentiated carcinoma (46.7 %). TNM
staging was closely related to short term effectiveness. (Table 4) The effectiveness
decreased with the increase of stage. That of Stage II was 90.3 %‚ III (66 +79/89 + 122 x
100) 68.7 % and IV 55.6 %. There was significant difference between these groups.
The total short term effectiveness decreased as die size of tumour increased. (Table 5)
Effective rate for tumours with diameter less than 8 cm ‘~vas 83.4 % (71 + 125/82 +
153 x 100) and that of tumours with diameter greater than 8 cm was 54.3 % (64 +
28/102 + 49 x 100). There was significant difference between these two groups.
One to five year survival rates were calculated by Kaplan-Meier‘s method in 1958.
There were 53 cases that died within one year. In the remaining 333 cases, 18 were
lost after one year. The results were listed in Table 6. One to five year survival rates
were 86.3 %‚ 76.4%, 58.8 %‚ 39.9 % and 29.5 %‚ respectively. Five year survival rate of
cases with squainous cell carcinoma is higher than that of cases with adenocarcinoma
and undifferentiated carcinoma. There was significant difference between them. Table
7 showed that the survival rates of stages II and IIIa were higher that that offstage IV.
While there was no cases of stage IV survived five years. The difference between
survival rates of different stages was statistically significant.
The survival rate of cases with tumour diameter of 4.0-8.0 cm, 35.7 % (40 + 44/82 +
153 x 100) was significantly higher than that of cases with tumour diameter longer
than 8.1 cm, 19.9 % (30/151)
Factors affecting effectiveness Number of electrodes and quantity of electricity affect
short term effectiveness. In 1987 to 1988, 40 cases of Jung cancer with diameter
www.BudwigCenter.com 7

8. between 4-6 cm were treated by only two electrodes, one anode and one cathode.
Electric quantity used was totally 200-300 coulomb. Clinical effectiveness of this group
showed that CR accounted for 17.5 % (7/40), PR 32.5 % (13/40) and CR + PR 50.0 %.
Animal experiments in 1988 showed that diameter of killing area around each
electrode was 2.5 cm and electric quantity needed was 100 coulomb per 1 cm
diameter of tumour tissue. Since February 1989, 42 cases of Jung cancer have been
treated by ECT with the above data. The effectiveness has been raised markedly with
CR 28.6% (12142), Pr 45.2 % (19/42) and CR+ PR 73.8%. There is significant difference
between these two groups.
Factors affect long term effectiveness are:(1) the stage of tumour; as shown in Table 4;
(2) size of tumour, as shown in Table 5; (3) pathological type of tumour, as shown in
Table 6; and (4) the recurrence rate of tumour. In the 386 cases, 99 cases accounted as
short term CR. Five years later, 18 cases (18.2 %) died of local recurrence, 21(21.2 %)
died of general metastasis, and 60 (60.6 %) survived over 5 years. Of the 179 cases
with PR, 55 cases (30.7 %) died of local recurrence, 70 (39.1 %) died of general
metastasis and 54 (30.2 %) survived over 5 years.
Discussion: An improved method, ECT, was applied for the treatment of 386 cases of
lung cancer. The short term and long term effectiveness is comparable with that of
surgical Operation and better than that of chemo- or radiotherapy. Therapeutic
effectiveness of ECT in treating middle stage Jung cancer with no metastasis is good.
72 cases of stage IV lung cancer and remote metastasis have been treated with ECT to
eliminate the primary focus. And other therapeutic measures including radio- and/or
chemotherapy and traditional Chinese medicines were combined with for the control
of remote metastasis. Patients had less suffering and their live might be prolonged.
The other therapeutic measures have also been used in combination with ECT for
treating cases with tumour size greater than 8 cm. Correct insertion of electrodes,
enough electric quantity and therapeutic time are important. Lung cancers that were
found to be inoperable during thoracotomy, could be treated with ECT right away.
Electrodes, hence, could be inserted wider direct vision. Good effectiveness could be
obtained by ECT in treating tumours which are solitary and its size Jess than 8 cm. ECT
is, however, a good method to treat late stage cancer patients who are inoperable and
not responsive to radio- and/or chemotherapy.
Typical cases
Mr. Wang, a 52 year-locater, R.N. 09803, complained ofchestpain and distress, and
bloody spots in sputum in January 1988. Chest X-ray film revealed a big shadow, 9.5 x
11 cm, in the upper lobe of the left Jung. Bronchoscopic examination discovered that
the mass obstructed the bronchus of the Jeft upper lobe. Squamous cell carcinoma
was diagnosed by pathological examination. (Fig. 1) He could not be operated due to
his cor pulmonale. He received ECT in March 1988. 8 electrodes (4 anodes and ~1
cathodes) were inserted transcutaneously. Voltage given was 8 V, Current 95 mA, and
electric quantity 1000 coulomb. (Fig. 2) After ECT, chest pain and bloody sputum
disappeared. Tumour reduced in size markedly when he was discharged. Six months
www.BudwigCenter.com 8

9. later, the tumour disappeared totally. Hi lived well and resumed his work after
following up for 5 years. (Fig. 3)
Mr. Cheng, a 45 year-old staff officer, R.N. 890016, complained of left chest pain and
distress, and cough in September 1992. Chest X-ray film revealed a shadow, 7.5 x 8.0
cm, in the left lower lobe and a shadow, 1.2 x 1.3 cm, in the right upper lobe. (Fig. 4)
Undifferentiated carcinoma was diagnosed by pathological examination. In October
1992, 6 electrodes (2 anodes and 4 cathodes) were inserted into the mass in the left
lower lobe. Voltage given was 7.8 V, current 88 am, and electric quantity 800 coulomb.
(Fig. 5) The tumour disappeared after ECT. Traditional medicines and FT 207 were
given to the patient for 3 months. Tumour in the right upper lobe disappeared also.
Two years later, he was found to be well without recurrence. (Fig. 6)
Table 1 Diameter (cm) of 386 cases with Jung cancers
Table 1 Diameter (cm) of 386 cases with Jung cancers
no of 4.0-6.0 6.1-8.0 8.1-10.0 >10
cases n % n % n % n %
squamous cell
carcinoma 203 47 23.2 86 42.3 47 23.2 23 11.3
adenocarcinoma 138 34 24.6 63 45.7 28 20.3 13 9.4
undifferentiated
carcinoma 45 1 2.2 4 8.9 27 60.0 13 28.9
total 386 82 21.3 153 39.6 102 26.4 49 12.7
Table 2 TNM stage of 386 cases with lung cancer
no of II IIIa IIIb IV
%
cases n n% n% n
squamous cell
carcinoma 203 65 32.0 46 22.7 58 28.6 34 16.7
adenocarcinoma 138 37 26.8 30 21.7 44 31.9 27 19.6
undifferentiated
carcinoma 45 1 2.2 13 28.9 20 44.4 11 24.5
total 386 103 26.7 89 23.1 122 31.6 72 18.6
Table 3 Short term effectiveness of 386 cases
no of CR PR NC PD CR +
PR
cases n% n% n% n% n
squamous cell
www.BudwigCenter.com 9

10. carcinoma 203 65 32.0 104 51.3 23 11.2 11 5.4 169 83.3
adenocarcinoma 138 32 23.2 56 40.6 23 16.7 27 19.5 88 63.8
undifferentiated
carcinoma 45 2 4.4 19 42.2 13 28.9 11 24.5 21 46.7
total 386 99 25.6 179 46.4 59 15.3 49 12.7 278 72,0
Table 5 Size of tumor and effectiveness
Diameter no of CR PR NC PD CR
n n n + PR
(cm) cases % % n% % n
4.0 - 6.0 82 27 32.9 44 53.6 8 9.8 3 3.7 71 86.6
6.1 - 8.0 I53 50 32.7 75 49.0 I8 11.8 10 6.5 125 8I.7
8.1 - 10.0 I02 22 2I.6 42 41.2 20 19.6 I8 17.6 64 62.7
>10.1 49 - - I8 36.7 13 26.6 18 36.7 18 36.7
total 386 99 25.6 179 46.4 59 15.3 49 I2.7 278 72.0
Table 6 One to five year survival rates of 386 cases
no ofI 2 3 4 5
% % % %
casesn n n n n
squamous cell
carcinoma 203 I83 90.I 163 80.3 130 64.0 91 44.8 72 35.5
adenocarcinoma I38 I20 87.0 I03 74.6 81 58.7 52 37.7 38 27.5
undifferentiated
carcinoma 45 30 66.7 29 64.4 16 35.6 I1 24.4 4 - 8.9
total 386 333 86.3 295 76.4 227 58.8 154 39.9 1I4 29.5
Table 7 Staging of cancers and 1-5 year survival rates
no of I 2 3 . 4
Stage n % % n5
cases % n n % n
II I03 95 92.2 89 86.4 8I 78.6 49 47.6 46 44.7
IIIa 89 79 88.8 7I 79.8 6I 68.5 42 47.2 36 40.4
IIIb I22 I05 86.I 9I 74.6 67 54.9 54 44.3 32 26.2
IV 72 54 75.0 47 65.3 I8 25:0 9 12.5 - -
total 386 333 86.3 298 77.2 227 58.8 I54 39.9 1I4 29.5
www.BudwigCenter.com 10

11. www.BudwigCenter.com 11